Vonoprazan manufacturers

Filters

None products found

vonoprazan

Tablets 10 mg, 20 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #40216

Established in 2008, the pharmaceutical group employs 11–50 professionals and operates across Ukraine, the EU, CIS, GCC, MENA and Asian markets. A CTD dossier owner and manufacturer, providing pharmaceutical product registration, regulatory affairs, GMP compliance, pharmacovigilance and commercialization services. GMP manufacturer working with its own manufacturing facility in Ukraine and EU-based CDMO partners. Its portfolio includes 120+ RX, OTC and food supplement products across 12 therapeutic areas. A CTD dossier owner and manufacturer supporting international product development and market expansion. A CTD dossier owner and manufacturer with expertise in regulatory lifecycle management.

vonoprazan

Tablets 10 mg, 20 mg

Dossier type
CTD
Dossier status
Under development
Country of origin
India
GMP approvals
WHO
Manufacturer #17643
This company specializes in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates, focusing on cost-effective solutions with a strong emphasis on quality. They offer contract development and manufacturing services (CDMO) for both New Chemical Entities (NCEs) and APIs, leveraging their globally compliant GMP facilities and expertise in modified release technologies. The company boasts state-of-the-art production lines capable of handling high-potent materials across various scales, catering to a wide range of pharmaceutical products including prescription medications and potentially over-the-counter drugs. While specific therapy areas aren't mentioned, they hold patents for their innovations and are actively involved in research and development. Their operations span multiple regions, including North America and the EU.

Manufacturer usually replies in 2 business days

vonoprazan

Tablets, film coated 10 mg, 20 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
Turkey
GMP approvals
FDA, EU GMP
Unavailable markets
Iraq
Manufacturer #13072
This pharmaceutical company, established in 1958, boasts a long history and operates across multiple regions, including Europe and North America. They specialize in the production of prescription medications, with a focus on three key therapy areas: oncology, immunology, and dermatology. Their principal dosage forms include tablets, capsules, and topical solutions. The company possesses GMP certifications and holds patents for several product innovations. With three production facilities and a logistics center, they prioritize efficiency and international expansion, aiming to become a global leader in the pharmaceutical industry.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

About vonoprazan

Vonoprazan manufacturers include the originator Takeda, which sells Takecab in Japan and Asia, Phathom Pharmaceuticals, which sells Voquezna in the US under licence, and generic producers in India and other markets. Vonoprazan is a potassium-competitive acid blocker (P-CAB), a newer class of acid suppressant that works faster and more consistently than proton pump inhibitors. It is used for erosive oesophagitis, heartburn and, with antibiotics, Helicobacter pylori infection. Pharmaceutical companies can source vonoprazan tablets and API through out-licensing, supply or technology transfer.

Vonoprazan key facts

Property

Vonoprazan

INN

Vonoprazan (as fumarate)

Molecular formula / weight

C17H16FN3O2S / 345.4 g/mol (base)

ATC code

A02BC08

Drug class

Potassium-competitive acid blocker (P-CAB)

Brand names

Takecab (Takeda, Japan and Asia); Voquezna, Voquezna Triple Pak, Voquezna Dual Pak (Phathom, US)

Originator

Takeda (Japan)

Dosage form and strengths

Tablets 10 mg and 20 mg

Indications (US)

Healing and maintenance of erosive oesophagitis; heartburn in non-erosive reflux disease; H. pylori infection (with antibiotics)

First approval

Japan, 2014–2015 (Takecab)

US approvals

H. pylori packs, May 2022; erosive oesophagitis, November 2023; non-erosive reflux heartburn, 2024

US exclusivity

NCE exclusivity recognised by FDA through 3 May 2032

US litigation

BDR sued the FDA in October 2026 over the exclusivity decision

Generic status

Generics available in India and other markets; none in the US

Vonoprazan manufacturers and licensing history

Takeda discovered vonoprazan and launched it in Japan as Takecab in 2015. It became widely used across Asia. In 2019, Phathom Pharmaceuticals licensed the US, European and Canadian rights.

In the US, the FDA approved Voquezna Triple Pak and Dual Pak for H. pylori in May 2022, Voquezna tablets for erosive oesophagitis in November 2023, and heartburn in non-erosive reflux disease in 2024. In June 2025, the FDA recognised 10 years of new chemical entity exclusivity, through 3 May 2032. In October 2026, BDR sued the FDA to challenge that decision, which could allow earlier generics if successful.

Vonoprazan generics are already available in India and some other markets. Buyers should confirm the salt form (fumarate), GMP status, a DMF and the patent and exclusivity position in each target market.

Vonoprazan dosage forms and dossier types

Vonoprazan is approved as 10 mg and 20 mg tablets, and in the US as co-packs with antibiotics.

Form

Strengths

Typical dossier

Notes

Vonoprazan tablets

10, 20 mg

US ANDA (after exclusivity); national CTD

Reference Takecab / Voquezna

Vonoprazan + amoxicillin (+ clarithromycin) packs

Per label

US ANDA; national

H. pylori treatment

Vonoprazan fumarate API

Bulk

DMF

Fumarate salt

Target market

Dossier format

Key requirement

United States

ANDA (eCTD)

NCE exclusivity to 3 May 2032; ongoing litigation

India, Asia, other

National CTD

Generics already available in some markets

European Union

EU CTD

Check approval and patent status

Vonoprazan regulatory and patent status

Vonoprazan was approved in Japan in 2014–2015 and in the US from 2022. In June 2025, the FDA recognised NCE exclusivity for Voquezna tablets through 3 May 2032. In October 2026, BDR sued the FDA over this, and Phathom says it will defend the exclusivity. Listed US patents run to 2028–2030. Check current exclusivity, litigation and patents before filing.

Vonoprazan mechanism of action and therapeutic use

Vonoprazan blocks the proton pump in stomach cells by competing with potassium, rather than binding permanently like proton pump inhibitors. It works from the first dose, does not need activation by acid and suppresses acid for longer. Vonoprazan is used for erosive oesophagitis, heartburn and, with antibiotics, H. pylori infection.

Vonoprazan licensing and sourcing

Vonoprazan suppliers and licensing partners typically offer dossier out-licensing, finished-product supply or technology transfer. Buyers usually compare GMP status, salt form, patent and exclusivity position, and territory availability. Current offers and supplier contacts are listed among the vonoprazan manufacturers on Pipelinepharma.

Frequently asked questions about vonoprazan

Who are the main vonoprazan manufacturers? Takeda is the originator and sells Takecab in Japan and Asia. Phathom Pharmaceuticals sells Voquezna in the US. Generic producers make vonoprazan in India and other markets.

When can generic vonoprazan launch in the US? The FDA recognised exclusivity through 3 May 2032. A lawsuit filed in October 2026 challenges this, so the date could change.

What is vonoprazan used for? Vonoprazan is used for erosive oesophagitis, heartburn from reflux disease and, with antibiotics, H. pylori infection.

What forms and strengths of vonoprazan are available? Vonoprazan is available as 10 mg and 20 mg tablets, and in the US as co-packs with antibiotics.

How is vonoprazan different from omeprazole? Both reduce stomach acid. Vonoprazan is a P-CAB that works from the first dose and gives stronger, more consistent acid control than proton pump inhibitors such as omeprazole.

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.